Summary.-Eighty-two per cent of tumour sections from 105 patients with lung cancer showed positive immunocytochemical localization of an anti-carcinoembryonic antigen (CEA) immunoglobulin free of antibody to normal cross-reacting antigen (NCA). The highest incidence was found in adenocarcinomas, and no association between staining and disease stage was found. There was a relationship between positive-staining tumours and preoperative and postoperative serum CEA levels of >,20 ng/ml, but the high incidence of CEA+, <20 ng/ml serum patients indicated that immunocytochemical localization was of little value in selecting patients for sequential serum monitoring. Staining for CEA was not prognostic but a preoperative serum CEA level 3z20 ng/ml was associated with a poor prognosis in patients undergoing radical surgery for lung cancer (P=0-043). This prognostic effect of CEA was seen mainly in patients whose tumours showed the greatest immunocytochemical localization (P=0 017) and in Stage III patients (P=0.04).
SINCE its original description (Gold & Freedman, 1965) carcinoembryonic antigen (CEA) has been identified in a variety of benign and malignant diseases, including lung cancer. It has been found in the serum (Lo Gerfo et al., 1971; Laurence et al., 1.972; Vincent & Chu, 1973; Newman et al., 1976) and shown by immunocytochemical techniques to be present in lung cancer tissue (Pascal et al., 1977; Goldenberg et al., 1978; Hill et al., 1979) . However, in the management of patients with lung cancer there is still disagreement as to its value as a prognostic indicator or as a reliable monitor of recurrence and response to treatment (Ford et al., 1979; GCropp et al., 1979) . In part, this may be due to differences in reagents and in sensitivities of the assays used in the various studies. This is particularly true of the in vitro localization investigations, where techniques such as immunodiffusion and immunoelectrophoresis are often used to assess the specificity of anti-CEA sera by * To wbom correspolldellce sboul(l be addressed.
excluding the presence of antibodies to the CEA-cross-reacting normal cross-reacting antigen (NCA). After showing specificity by these methods, antisera are then used in more sensitive immunocytochemical tests to determine the expression of CEA and the possibility of cross-reacting antibodies being detected in these tests is not considered further.
The objectives of this investigation were to use an anti-NCA-free anti-CEA antibody in an indirect immunoperoxidase test to determine the expression of CEA in lung-cancer tissue sections; to examine whether there was a correlation between the presence of CEA staining and serum levels of the antigen, and whether tissue staining could predict those patients in whom sequential monitoring might be of value; and finally, to investigate whether the presence of CEA in the tumour or in the serum was of prognostic significance in patients undergoing radical surgery for lung cancer. (Mathews, 1973) . Well differentiated squamous-cell carcinomas were not available for study, as patients with this type of lung cancer were not eligible for the clinical trial because of their better prognosis than other histological types. Patients were staged using clinico-pathological criteria (Mountain, 1976) . Serum samples were obtained where possible preoperatively; monthly after surgery for 3 months; then at 3-monthly intervals for 3 years and thereafter at 6-monthly intervals.
Antisera.-A sheep anti-CEA immunoglobulin (Ig), supplied by Dr A. R. Bradwell, Immunodiagnostics Research Laboratory, University of Birmingham, was used in this study. Details of the preparation of this antibody and its in vivo use have been reported elsewhere (Dykes et al., 1980) . Before fractionation, the antiserum had been absorbed once with glutaraldehyde-polymerized human serum and 3 times with glutaraldehyde-fixed normal tissue from colon, spleen, lung and liver, until it gave a single line on immunoelectrophoresis. After ammonium sulphate fractionation and DE52 chromatography, this Ig still cross-reacted with NCA, as determined by immunoperoxidase staining of NCA-containing myeloid cells in sections of normal human spleen, and leukaemic cells from patients with chronic myeloid leukaemia (CML). The Ig was absorbed with polymerized spleen until it was negative with spleen and CML cells with which it had previouslv been positive in the immunoperoxidase test (a further 3 absorptions). This Ig showed characteristic luminal localization on sections from CEA-secreting colonic carcinomas, and stained liver metastases from colon-cancer primaries. It was then used in these experiments.
For a negative control in the immunoperoxidase test, anti-CEA activity was removed from an aliquot of this Ig by absorption with CEA prepared and purified in this laboratory by Mr J. A. Griffin and Mr C. S. Woodhouse, using the method of Pritchard & Egan (1978) without the final ConA-affinity purification. An immunosorbent column was prepared by coupling 2-5 mg of CEA to AH Sepharose, using the method of Burtin & Gendron (1978) . The CEA used for coupling was from a different source from that used for raising the anti-CEA serum. After absorption, the anti-NCA-free anti-CEA Ig no longer stained sections from CEA-secreting colon cancers, and was used as a control in the immunoperoxidase test. A rabbit anti-sheep IgG-horseradish peroxidase conjugate (Nordic) was used as the second antibody in the test.
Immunoperoxidase technique.-The twostage immunoperoxidase technique as detailed by Heyderman (1979) was used. After blocking aldehyde groups with 0.02% sodium borohydride, a step was introduced in which 100 ,l of a 1/25 dilution of normal rabbit serum was incubated with the sections for 10 min, followed by washing with PBS. One hundred ,ul of a 1/50 dilution of anti-CEA Ig in 1% BSA in PBS was then incubated with the sections for 30 min. After the next washing step, 100 ,ul of a 1/80 dilution of rabbit antisheep IgG-peroxidase conjugate was incubated for 30 min with the sections, and the rest of the test procedure performed as described by Heyderman (1979) . Controls in4 cluded 2 sections from the same paraffin block treated with a 1/50 dilution of the CEA absorbed anti-CEA or a 1/100 dilution of 1% BSA instead of the anti-CEA Ig. The rest of the technique was identical.
The incubation with normal rabbit serum was found to be an essential step. In initial experiments this was omitted, and it was found necessary to absorb the rabbit antisheep conjugate with glutaraldehyde-polymerized human tissue to reduce the background non-specific staining. However, when the anti-NCA-free anti-CEA Ig was then used, it would only stain lung tumours after the sections had previously been treated with 0.1% trypsin, resulting in a loss of CEA specificity (Ford et al., 1980a) . This problem was overcome by incubating with normal rabbit serum after the step of blocking aldehyde groups. Absorption of the conjugate and treatment of the sections with trypsin were then no longer necessary.
Interpretation of staining. al., 1972; Booth et al., 1973) . The upper limit of the normal range with this assay is 15 ng/ml, and the use of this test for measuring CEA in serum samples from lung-cancer patients has been reported previously Comparison of immunocytochemical anti-CEA localization with serum CEA levels is shown in Table II for the 86 patients for whom there were both preoperative and postoperative serum samples available for assay. The upper limit of normal with this assay was 15 ng/ml. Because patients with lung cancer are often bronchitic and cigarette smokers, and as both bronchitics and smokers often have slightly higher serum CEA levels, 20 ng/ml was selected as a cut-off for the 
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CEA+, <20ng/ml patients in the 2 groups. We therefore looked only at patients who had recurred and died, and for whom we had pre-and postoperative serum samples using 20 ng/ml as the cut off. This made no difference to the preoperative group but it did result in a small reduction to 69% in the percentage of CEA+, < 20ng/ml patients in the postoperative group. In terms of prognosis, when looked at by logrank and life-table analysis, there was a slight non-significant difference between patients with Type 2 staining and patients with negative or Type 1 tumours (Fig. la) . When positive was compared with negative, without subdivision, there was no difference between the groups (Fig. lb) . The prognostic influence of a preoperative CEA level < 20 ng/ml, 20-49 ng/ml or 3 50 ng/ml is shown in Fig. 2a . It can be seen that the 20-49 ng/ml and 3 50 ng/ml groups have the same survival characteristics, but that the < 20 ng/ml group has a better prognosis. For this reason we felt justified in combining 2 groups and comparing < 20 ng/ml with 3 20 ng/ml (Fig. 2b) (P=0-017, Fig. 3a ). There wei patients (4) with 3 20 ng/ml iD 2 category to make a similar c Looked at in relation to histo were only small numbers of I the 3 20ng/ml group for any histological type. However, i with PDSCC tumours, no diffi seen; in the anaplastic group SCA and non-SCA) the 3 20ng/i had a worse survival than pal < 20 ng/ml (non-significant) ai the adenocarcinoma group did this difference approach significance (P = 0.08). With regard to Stage, there was no difference in survival between Stage I patients with < 20 or 3 20 ng/ml. The prognostic significance of preoperative CEA was only seen in Stage III patients where patients with 3 20 ng/ml had a worse survival (P = 0*04, Fig. 3b ). There were insufficient Stage II patients for analysis. 1996 figure of 85.5% is also higher than that reported by others for all squamous-cell e CEA carcinomas; 22% (Pascal et al., 1977) and Staining;
24% (Goldenberg et al., 1978) and 69% that 26% (7/27) of adenocarcinomas of the lung had very high ( 3 50 ng/ml) preoperative levels, a much higher percentage than any of the other histological types . Initially, others were unable to detect such an association with the histological type of lung cancer (Laurence et al., 1972 ) but more recently this has been confirmed (McKenzie et al., 1977; Vincent et al., 1979) .
We found no difference in overall positive frequency between patients with Stage I and Stage III disease, though there was a higher incidence of Type 1 staining in Stage III patients. Extent of disease (as defined by stage) was, therefore, not reflected by immunocytochemical positivity for CEA in our patients. An interesting finding was that, although there was a good correlation between a preoperative CEA level of 3 20 ng/ml and immunocytochemical localization (92%), 75% of patients with levels lower than the cut-off were also CEA+ in the immunoperoxidase test. A similar result was obtained in the postoperative group as well as in the combined pre-and/or postoperative group. Taking the higher cut-off of 3 50 ng/ml the correlation with total staining and Type 1 staining was I 00%/ in the preoperative group but lower in the other 2 groups. Even when these data were "corrected" for the fact that many patients were alive without recurrence, and only patients who had recurred and died were analysed, there were still over 6900 positively stained tumours in patients with CEA levels of < 20 ng/ml either preoperatively or postoperatively.
One of the aims of this study was to investigate whether there was a correlation between immunocytochemical staining for CEA and preoperative and postoperative serum levels of the antigen, so that we could determine whether tissue staining might be valuable in predicting those patients in whom sequential serum monitoring might be of benefit. In this study over 82% (88% in the "corrected" group) of patients who had 3 20 ng/ml either preoperatively or postoperatively, did stain 11 for CEA, but a sizeable percentage (over 7500, or 69% in the "corrected" group) with <20 ng/ml also had positively stained tumours. It would appear, therefore, that knowledge of the immunocytochemical localization of anti-CEA antibodies would be of no value to the clinician in selecting patients for sequential monitoring. A possible explanation for this may be that the 20 ng/ml cut-off is not the appropriate threshold. We feel, however, that the cut-off we have chosen is valid, because it is higher than the upper limit of the normal range in the radioimmunoassay (15 ng/ml) thereby excluding patients with small transitory rises above the limit, and in particular because patients with levels 20-49 ng/ml and 3 50 ng/ml preoperatively have a similar prognosis (Fig. 2a) .
A criticism of immunocytochemical investigations is that with a 5-7,um section one is looking at a very small, selected area of the tumour. This is more of a problem when staining cannot be demonstrated, and it might be argued that the CEA-secreting area was missed when the sections were cut. That was not a problem in this study because of the high incidence of positive staining. However, it is conceivable that had we been able to look at a large number of sections from each tumour we might have found sections in which some of the Type 2 staining tumours were negative and the negative tumours were positive. This is one of the reasons why the positives were analysed in 2 groups. We did not feel justified in combining the Type 2 and negative groups, as within the strict definition of a positive as any staining of a tumour more than in a CEA-absorbed control, Type 2 tumours were definitely CEA+. There was no association of staining with prognosis, irrespective of the type of staining, and the 19 patients with CEA-tumours had an identical survival curve to that of patients with CEA+ tumours (Fig. la, & b) . However, a preoperative serum CEA level of 3 20 ng/ml was associated with a bad prognosis. Although the cut-off level and method of assay differ, these results are similar to those reported for adeno-and squamous carcinomas of the lung (Concannon et al., 1978) where all patients with > 6 ng/ml died and survivors were only found in the < 6 ng/ml group. However, the patients studied by Concannon were all who had a thoracotomy and not just those who received radical surgery, as in this study. Dent et al. (1978) found no prognostic effect of preoperative CEA level in 20 patients with resected lung cancers, but patients with a CEA value of > 5 ng/ml 3 months after surgery had a significantly worse prognosis than those with < 5 ng/ml. However, in a much larger series of 118 patients with surgical resection, Vincent et al. (1979) found a significantly worse prognosis for patients with a preoperative CEA level > 2-5 ng/ml. Although the cutoff level is different due to different assay sensitivities, this parallels our experience, and the 2 studies are similar in terms of the numbers of patients studied and in the surgical treatment. A similar result was obtained by Stokes et al. (1980) in 43 patients followed for 2 years after complete resection of a primary lung cancer, when a preoperative level of < 21 ,ug/l was associated with a significantly better prognosis than 3 21 ,ug/l.
When looked at in relation to other factors which might influence the production of CEA, the prognostic effect of a preoperative CEA level of 3 20 ng/ml was only seen in tumours with the greatest amount (Type 1) of anti-CEA staining (P=0*017, Fig. 3a ) and in patients with Stage III disease (P = 0-04, Fig. 3b) .
In this study, we have demonstrated that the preoperative CEA level is a prognostic indicator in patients who undergo radical surgery, and that immunocytochemical localization of anti-CEA Ig on sections from lung cancers does not enable us to reliably predict those patients for whom postoperative CEA monitoring might be of value. Although the antigenic nature of lung cancers is being actively investigated by a number of groups, including our own (Ford et al., 1980b) and potential tumour-associated markers have been identified, CEA remains the bestcharacterized tumour-associated marker in lung cancer at present. The high percentage of lung tumours secreting CEA, as detected immunocytochemically, is encouraging in terms of the potential use of anti-CEA antibodies for radioimmunodetection (Goldenberg et al., 1979; Dykes et al., 1980) and may have important clinical applications in terms of targeted therapy in the future.
